argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111
3 June 2016, Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced data published in conjunction with the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting (Chicago, USA)
presenting efficacy and safety data from its ARGX-111 Phase 1 expansion study in patients with MET amplified tumors. The data confirm ARGX-111 to have a favorable safety profile and to continue to show signs of anti-tumor activity. The abstract can be accessed here.
In addition, data from preclinical studies demonstrate depletion of MET-positive myeloid-derived suppressor cells (MDSCs) by ARGX-111. These data provide an exciting new perspective for therapeutic intervention in MET cancer biology in targeting both the tumor cells and the tumor microenvironment.